Clinical Trial Update: Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for atezolizumab plus Bacillus Calmette-Guérin (BCG) in high-risk BCG-naïve non-muscle invasive bladder cancer (BladderGATE); curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: Fundacion Oncosur | Conditions: Invasive Bladder Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING